Truly, the described clinical scenario1 had its origins in 1999 with the discovery and ongoing characterization of IL-18 binding protein (IL-18BP) by Novick et al.2 We are grateful for their correspondence detailing the salient properties of this molecule.3 Regrettably, our original article was unable to include such details due to space limitations and the need to provide sufficient detail on the clinical scenario presented. We obviously agree that this molecule is well suited to the task of therapeutically blocking IL-18.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qodmrq
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Purpose: The MHC-unrestricted activity of cytokine-induced killer (CIK) cells against chemo-surviving melanoma cancer stem cells (mCSC) was...
-
Publication date: 18 April 2017 Source: Cell Reports, Volume 19, Issue 3 Author(s): David Estoppey, Chia Min Lee, Marco Janoschke, Boon He...
-
Induced overexpression of CD44 associated with resistance to apoptosis on DNA damage response in human head and neck squamous cell carc...
-
Vol.20 No.1 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2seUCMY via IFTTT
-
Abstract This paper addresses the hybrid consensus-based formation keeping problem for nonholonomic mobile robots in the presence of a nov...
-
Current treatments for generalized pustular psoriasis are unsatisfactory. We applied recently-developed techniques for transcriptomic analys...
-
Downregulation of mouse CCR3 by lentiviral shRNA inhibits proliferation and induces apoptosis of mouse eosinophils. Mol Med Rep. 2016 ...
-
The influence of different types of brackets and efficacy of two chlorhexidine mouthwashes on oral hygiene and the incidence of white s...
-
A randomised controlled trial comparing transnasal humidified rapid insufflation ventilatory exchange (THRIVE) pre-oxygenation with fac...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου